Screening prostate-specific antigen (PSA) at mid-life may help identify prostate cancer later in life

Screening prostate-specific antigen PSA

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body.

However, the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk.

Smarter screening strategies that can improve the accuracy of diagnosing lethal prostate cancer are urgently needed.

Through a prospective study of US men, scientists from Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health have found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future risk of lethal prostate cancer later in life.

Their findings suggest that screening PSA levels in men at mid-life may help identify those who are at greater risk and should be monitored more closely.

The current study leverages data from the Physicians’ Health Study (PHS), a study that tested aspirin and risk of cardiovascular outcomes.

The PHS began in 1982 and US male physicians who took part in it provided blood specimens before the trial began.

Those blood samples, and the detailed questionnaires filled out by the study participants over the next 30 years, gave researchers the information they needed to conduct the current research project.

Using information from 234 men who were diagnosed with prostate cancer, including 60 who developed lethal prostate cancer, and 711 controls, all between 40 and 59 years of age at the start of the trial, the research team measured PSA levels from stored plasma samples and followed the men’s outcomes over time.

The researchers found that this single, baseline PSA level measured at midlife could accurately predict future risk of prostate cancer.

Of the lethal prostate cancer events, 82%, 71% and 86% occurred in men with a baseline PSA above the median at ages 40-49, 50-54 and 55-59, respectively.

The study also found that men who had a PSA below median (<1.0 ng/ml) at age 60 were unlikely to develop lethal prostate cancer in the future.

These results support the recommendation that risk-stratified screening for prostate cancer based on mid-life PSA should be considered in men aged 45 to 59.

The study does not imply prostate biopsy or definitive treatment is immediately required in younger men with higher PSA levels at baseline, as this could lead to over diagnosis.

Rather, these men should undergo more intensive PSA screening to enable earlier identification of cancer and potential cure while still possible.

The authors note that study limitations include that the study population consists primarily of Caucasian men, includes limited lethal events and that an unknown proportion of participants may have undergone opportunistic screening prior to the study.

Follow Knowridge Science Report on Facebook, Twitter and Flipboard.

Citation: Preston MA et al. (2016). Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. Journal of Clinical Oncology, published online. DOI: 10.1200/JCO.2016.66.7527.
Figure legend: This image is credited to